Explore expert articles, in-depth analysis and stay informed with the latest in virology from Advanced Virology.
We are pleased to announce the addition of five new Bundibugyo Ebolavirus Virus-Like Particle (VLP) products to our online catalog, providing researchers with safer, high-quality tools for filovirus vaccine development,...
Modern biomedical research depends on a simple economic principle: laboratories purchase standardized reagents whenever specialized manufacturers can produce them more efficiently than individual research groups.
These newly available strains include wild-type and reporter virus variants across four important viral families, offering greater flexibility for a wide range of research applications.
Advanced Virology now offers custom-order Bundibugyo Ebolavirus VLPs designed for assay development, immunology, vaccine research, diagnostics, and countermeasure evaluation.
Every year, preclinical research in the United States wastes an estimated $28 billion on irreproducible studies...
Whether developing vaccines, testing antivirals, or building diagnostic assays, success depends heavily on the fidelity of the virus stocks used during R&D.
In recent years, reverse genetics has emerged as a more precise and powerful alternative to serial passaging, offering a range of advantages in the production of virus stocks.
Utilizing Reporter Viruses in Antiviral Drug Discovery Antiviral drug discovery is a cornerstone of modern infectious disease research. Rapid screening of compound libraries and accurate quantitation of virus replication are...
We’re pleased to announce that Advanced Virology is now live on Scientist.com, providing research organizations with another convenient channel to access our virology products and services.
Subscribe to our newsletter for industry insights and research updates.
Subscribe to our newsletter for industry
insights and research updates.